Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
about
Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapyLeishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamstersThe Abl and Arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infectionTesting of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice.Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and In Silico Studies.Leishmania chagasi T-cell antigens identified through a double library screenBiochemical and biological characterization of the protective Leishmania pifanoi amastigote antigen P-8.In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasisRecombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infectionLeishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis.Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis.Development of a stable Leishmania expression vector and application to the study of parasite surface antigen genes.Leishmaniasis: current status of vaccine developmentSubunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasisLeishmania LPG3 encodes a GRP94 homolog required for phosphoglycan synthesis implicated in parasite virulence but not viabilityImmunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasisA review of adjuvants for Leishmania vaccine candidates.Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection.Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis.Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune responseCharacterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine modelCloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages.Leishmaniases of the New World: current concepts and implications for future researchAmastigote stage-specific monoclonal antibodies against Leishmania major.Experimental models in vaccine research: malaria and leishmaniasis.Parasite antigens recognized by patients with cutaneous leishmaniasis.Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c miceAdjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response
P2860
Q28343709-2E9305B4-87B8-4ACB-8DC0-7FBAC16BC1EFQ28480398-50FAC6F5-35AE-4D91-A296-36065B522A81Q28594369-5D23AC1E-3A52-4F25-BCC2-8084C70DA88BQ30444062-9E87AA2F-A7F3-4650-BC4A-415E7186E241Q30452825-0737C948-14E1-434E-AC53-0FAA85460610Q31162563-B76402A5-6F7F-48F6-B10D-E90CD251B377Q33258365-FBE053BC-A323-4ECD-B74D-EA36725B2786Q33552567-0818ABDF-537D-4F4E-8BF5-29AD0CADD91FQ33559668-C8389F8F-3F0C-4F25-A6C8-5470617E0B86Q33604990-8AADF071-35D8-4234-BBE3-8A865F48EC11Q33756069-BAA425DD-DAC8-430E-A788-C6813EFADABDQ33868496-87875C3A-BCE4-4998-9AC0-BBA7EE9002F6Q33925389-57F5EE37-D9C0-45AB-A551-03BE943BB527Q33941719-89284666-CA93-464B-9392-6DEF6550CD1FQ34003547-F1018D29-389A-4200-9B91-627E2B774319Q34008441-56CF4D66-A488-4685-9F8C-769875BB3817Q34090960-3A8A5849-BCF3-4E29-B368-D41E573239F9Q34128082-AAF0DD07-72F0-421B-AABB-6B7457E873FBQ34521577-82411F47-7D1F-43E6-B8F9-84BD1AD81AAEQ34647684-809EFBC5-3D61-43F1-9D67-293BCA9F7B34Q35011520-8144A27F-1442-4BBE-A99E-8D28209D13F6Q35105685-572E4B8C-13E5-4790-BB2F-8EC038447025Q35437937-9D589A42-540A-4252-9A8C-BE39646E286FQ35448239-99378172-9CD1-4949-8C7F-F5BA783DF836Q35548417-87EF243A-1DEA-471F-84AB-2062E39CA02EQ36365469-62A57B1B-25AD-4D01-B399-B5CA445118B3Q36640255-E70E2AD7-A181-4DA2-8B37-7A2AA8CF5E77Q37006929-A84EE49D-256B-4B6E-8BDB-A9D8EA13E491Q37371348-7370A56D-B6FF-49C0-9494-5267A20FAA91Q39098964-A42BEF3A-C439-4F5D-819D-211AFA989A97Q39672345-FEA5AC8A-ABCC-4AAF-822D-5D88E7ED53F0Q39830157-48BC714F-A38E-487F-8FAD-75B80930E650Q40630924-168348FE-B9F1-4B1B-A46A-727F782EE517Q58836359-F958D7BD-9C43-4554-832E-1011F15B1DCC
P2860
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1988
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
@en
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
@nl
type
label
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
@en
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
@nl
prefLabel
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
@en
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
@nl
P2860
P1476
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
@en
P2093
D McMahon-Pratt
P2860
P304
P407
P577
1988-12-01T00:00:00Z